FRA:BRM - Deutsche Boerse Ag - US1101221083 - Common Stock - Currency: EUR
FRA:BRM (3/7/2025, 7:00:00 PM)
57.3
+2.37 (+4.31%)
The current stock price of BRM.DE is 57.3 EUR. In the past month the price increased by 4.68%. In the past year, price increased by 16.82%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 67 | 760.43B | ||
LLY.DE | ELI LILLY & CO | 66.98 | 760.15B | ||
ZEG.DE | ASTRAZENECA PLC | 21.82 | 446.45B | ||
JNJ.DE | JOHNSON & JOHNSON | 16.81 | 372.31B | ||
1JNJ.MI | JOHNSON & JOHNSON | 16.61 | 367.98B | ||
NOV.DE | NOVO NORDISK A/S-B | 26.21 | 355.97B | ||
SNW.DE | SANOFI | 14.32 | 275.64B | ||
SAN.PA | SANOFI | 14.27 | 274.84B | ||
1SAN.MI | SANOFI | 14.19 | 273.18B | ||
6MK.DE | MERCK & CO. INC. | 12.64 | 224.82B | ||
1MRKX.MI | MERCK & CO. INC. | 12.47 | 221.79B | ||
PFE.DE | PFIZER INC | 8.69 | 140.81B |
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The firm's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY US
Employees: 34100
Company Website: https://www.bms.com/
Investor Relations: https://www.bms.com/investors.html
Phone: 16092524621
The current stock price of BRM.DE is 57.3 EUR. The price increased by 4.31% in the last trading session.
The exchange symbol of BRISTOL-MYERS SQUIBB CO is BRM and it is listed on the Deutsche Boerse Ag exchange.
BRM.DE stock is listed on the Deutsche Boerse Ag exchange.
31 analysts have analysed BRM.DE and the average price target is 57.6 EUR. This implies a price increase of 0.52% is expected in the next year compared to the current price of 57.3. Check the BRISTOL-MYERS SQUIBB CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a market capitalization of 116.28B EUR. This makes BRM.DE a Large Cap stock.
BRISTOL-MYERS SQUIBB CO (BRM.DE) currently has 34100 employees.
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a support level at 56.97 and a resistance level at 57.31. Check the full technical report for a detailed analysis of BRM.DE support and resistance levels.
The Revenue of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to decline by -4.64% in the next year. Check the estimates tab for more information on the BRM.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a dividend yield of 4.12%. The yearly dividend amount is currently 2.22. Check the full fundamental report for a detailed analysis of BRM.DE dividend history, reliability and sustainability.
BRISTOL-MYERS SQUIBB CO (BRM.DE) will report earnings on 2025-04-24, before the market open.
The PE ratio for BRISTOL-MYERS SQUIBB CO (BRM.DE) is 54.57. This is based on the reported non-GAAP earnings per share of 1.05 and the current share price of 57.3 EUR. Check the full fundamental report for a full analysis of the valuation metrics for BRM.DE.
ChartMill assigns a technical rating of 6 / 10 to BRM.DE. When comparing the yearly performance of all stocks, BRM.DE is one of the better performing stocks in the market, outperforming 76.39% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to BRM.DE. BRM.DE has an average financial health and profitability rating.
Over the last trailing twelve months BRM.DE reported a non-GAAP Earnings per Share(EPS) of 1.05. The EPS decreased by -84.8% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -9.66% | ||
ROE | -54.78% | ||
Debt/Equity | 2.93 |
ChartMill assigns a Buy % Consensus number of 68% to BRM.DE. The Buy consensus is the average rating of analysts ratings from 31 analysts.
For the next year, analysts expect an EPS growth of 498.05% and a revenue growth -4.64% for BRM.DE